E
STRO icon

Ergoteles’s Sutro Biopharma STRO Stock Holding History

Ergoteles’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,169
Closed -$54.4K – 743
2023
Q2 		$54.4K Buy
+1,169
New +$58.2K ﹤0.01% 951
2022
Q3 		– Sell
-8,431
Closed -$439K – 1971
2022
Q2 		$439K Buy
8,431
+5,857
+228% +$327K 0.01% 899
2022
Q1 		$212K Buy
2,574
+972
+61% +$92.5K 0.01% 971
2021
Q4 		$238K Buy
+1,602
New +$287K 0.01% 950

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Ergoteles's STRO Position: Q3 2023 in Review

Ergoteles sold out of Sutro Biopharma (STRO) in Q3 2023, closing a stake of 1,169 shares — an estimated $54.4K sold.

Ergoteles first reported a position in STRO in Q4 2021 and held it in 4 quarters. The position peaked at $439K in Q2 2022. 108 funds tracked by Wall St. Rank hold STRO as of Q3 2023.

  • Ergoteles reported no remaining Sutro Biopharma position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 1,169 Sutro Biopharma shares in Q3 2023, an estimated $54.4K.
  • Ergoteles first reported a position in Sutro Biopharma in Q4 2021 and held it in 4 quarters.
  • Ergoteles's Sutro Biopharma position peaked at $439K in Q2 2022.
  • 108 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.